Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 26;4(2):73-90.
doi: 10.5662/wjm.v4.i2.73.

Novel agents and new therapeutic approaches for treatment of multiple myeloma

Roberto Ria  1 , Antonia Reale  1 , Angelo Vacca  1
Affiliations
Review

Novel agents and new therapeutic approaches for treatment of multiple myeloma

Roberto Ria et al. World J Methodol. .

Abstract

This review summarizes the therapeutic strategies and the drugs actually in development for the management of myeloma patients. Multiple myeloma is caused by the expansion of monoclonal plasma cells and secretion of M-protein (immunoglobulins, Bence Jones protein and free light chains). Multiple myeloma still remains an incurable disease with a high incidence rate in the elderly, despite the introduction of several new therapeutic agents (bortezomib, lenalidomide and thalidomide) which have changed its natural history. The high heterogeneity of this disease leads to large differences in clinical responses to treatments. Thus, the choice of the best treatment is a difficult issue. However, the introduction of new drugs has made it possible to achieve high response rates and good quality responses with long-term disease control. Interactions between tumor cells and their bone marrow microenvironment play a pivotal role in the development, maintenance, and progression of myeloma, inducing also drug resistance. These knowledges have improved treatment options, leading to the approval of new drugs which not only target the malignant cell itself, but also its microenvironment. These agents are in preclinical/early clinical evaluation and they appear to further improve disease control, but their use is still not approved outside of clinical trials.

Keywords: Immunomodulators; Multiple myeloma; New drugs; Proteasome inhibitors; Target therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progress in the treatment of multiple myeloma[127].
Figure 2
Figure 2
Chemical structure of bortezomib and new proteasome inhibitors carfilzomib, delanzomib (CEP18770), marizomib (NPI-0052) and ixazomib (MLN9708).
Figure 3
Figure 3
Chemical structures of thalidomide and its analogues, lenalidomide (CC-5013) and pomalidomide (CC-4047).
See this image and copyright information in PMC

Similar articles

  • Multiple Myeloma: New Insights and Therapeutic Approaches.
    Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2000:147-165. doi: 10.1182/asheducation-2000.1.147. Hematology Am Soc Hematol Educ Program. 2000. PMID: 11701540
  • Current therapeutic strategy for multiple myeloma.
    Suzuki K. Suzuki K. Jpn J Clin Oncol. 2013 Feb;43(2):116-24. doi: 10.1093/jjco/hys215. Epub 2013 Jan 4. Jpn J Clin Oncol. 2013. PMID: 23293370 Review.
  • New treatments for myeloma.
    Azaïs I, Brault R, Debiais F. Azaïs I, et al. Joint Bone Spine. 2010 Jan;77(1):20-6. doi: 10.1016/j.jbspin.2009.10.009. Epub 2009 Dec 23. Joint Bone Spine. 2010. PMID: 20031467 Review.
  • New drugs for myeloma.
    Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. Richardson PG, et al. Oncologist. 2007 Jun;12(6):664-89. doi: 10.1634/theoncologist.12-6-664. Oncologist. 2007. PMID: 17602058 Review.
  • The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG, Hideshima T, Mitsiades C, Anderson KC. Richardson PG, et al. J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. doi: 10.6004/jnccn.2007.0015. J Natl Compr Canc Netw. 2007. PMID: 17335684 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–1060. - PubMed
    1. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol. 2010;28:2612–2624. - PubMed
    1. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36 Suppl 1:S3–12. - PMC - PubMed
    1. Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol. 2012;2012:157496. - PMC - PubMed
    1. Gertz MA, Ansell SM, Dingli D, Dispenzieri A, Buadi FK, Elliott MA, Gastineau DA, Hayman SR, Hogan WJ, Inwards DJ, et al. Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc. 2008;83:1131–1138. - PubMed

LinkOut - more resources